CATX Perspective Therapeutics, Inc.
$1.10▼ -8.84%
Healthcare
Other
Volume 5.11M
Avg Volume (10D) 2.59M
Key Metrics & Fundamentals
Market Cap
$125.90M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.06 - 6.16
% vs 50 MA
-55.79%
% vs 200 MA
-66.09%
RSI-14
21.4
MACD Histogram
-0.0900
Beta (1Y vs SPY)
1.55
Free Cash Flow
-$34.85M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$25.77M
COGS
–
Operating Exp
$29.26M
Operating Income
-$29.26M
EBIT
-$29.26M
Pretax Income
-$26.98M
Net Income
-$26.79M
EPS (Diluted)
-0.22
Price & Volume History
Loading chart…
Recent News
Perspective Therapeutics Facing Execution Risks in Bamzireotide Navoxetan's Development, RBC Says
MT Newswires · Oct 26, 2026 11:47 AM ET
RBC Downgrades Perspective Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $14, Keeps Speculative Risk
MT Newswires · Oct 26, 2026 6:28 AM ET
Wedbush Adjusts Price Target on Perspective Therapeutics to $9 From $11, Keeps Outperform Rating
MT Newswires · Oct 26, 2026 5:08 AM ET
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
MarketBeat · Oct 23, 2026 5:02 PM ET
Perspective Reports 'Encouraging' Bamzireotide Profile in Tumor Trial
MT Newswires · Oct 23, 2026 12:32 PM ET
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
GlobeNewswire · Oct 23, 2026 10:49 AM ET
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Zacks · Oct 9, 2026 6:42 AM ET
Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell
MT Newswires · Oct 8, 2026 6:53 AM ET
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
GlobeNewswire · Oct 8, 2026 6:16 AM ET
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
GlobeNewswire · Oct 7, 2026 6:16 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CATX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.